What Biossil does

Biossil is a Toronto-based AI-native biopharma company founded in 2023 that operates a proprietary drug rescue platform designed to identify promising molecules from failed clinical trials and reposition them for new therapeutic indications. Rather than conducting de novo drug discovery, the company acquires or licenses failed or deprioritized candidates and applies generative and predictive machine learning — including a referenced GEMOD (Gene Embedding to Mechanism of Action Distance) analytical framework — to assess their potential in alternative disease contexts. The pipeline spans late-stage clinical programs in sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease, with additional trials launching in hereditary xerocytosis, cisplatin-associated nephrotoxicity, basal cell carcinoma/squamous cell carcinoma, MPS VI, GI-acute radiation syndrome, and premature ovarian failure, and future programs in portal hypertension, radiation dermatitis, necrotizing soft tissue infection, vaso-occlusive crises, and diabetic cardiomyopathy.

The portfolio has been assembled through a combination of in-licensing and asset acquisitions: in October 2025 the company secured exclusive global rights to Medivir's topical HDAC inhibitor remetinostat (Phase 2, up to USD 60M in potential milestones and royalties) and acquired Galera Therapeutics' dismutase mimetics portfolio (avasopasem and rucosopasem, up to $105-108.5M in total deal value), assuming all development and commercialization obligations. The company exited stealth in April 2026 with approximately $70 million USD in equity funding from OpenAI, Founders Fund, 137 Ventures, DRI Healthcare Trust, Golden Ventures, Modern Capital, Panache Ventures, Quiet Capital, and Staircase Ventures, and operates from headquarters in Toronto with a secondary office in Boston, employing roughly 30 staff led by CEO Alexander I. Mosa (MD PhD) and Co-founder Anthony Mouchantaf (JD MBA).

Biossil's business model is licensing- and milestone-based: the company generates future revenue through drug development outcomes, partnering deals, milestone payments, and ultimately royalties upon successful development and commercialization of its repositioned candidates. As a clinical-stage company with no approved products, it currently has no commercial product revenue; distribution post-approval is anticipated to flow through traditional pharmaceutical channels including wholesalers, pharmacies, hospitals, and specialty pharmacies. End users are patients with life-threatening and rare conditions across oncology, neurodegeneration, hematology, fibrotic disease, and rare genetic disorders.

Name

Biossil

Legal name

Biossil

Website

https://www.biossil.co/

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Biossil is a Toronto-based AI-native biopharma company that uses a proprietary machine learning platform to identify and reposition promising molecules from failed clinical trials, developing late-stage treatments for patients with life-threatening and rare diseases across oncology, hematology, and neurodegeneration.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• AI drug discovery
• Drug repositioning platform
• Clinical stage biopharma
• Failed trial molecules
• Rare disease therapeutics

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Drug Development and Licensing: Biossil acquires or licenses molecules from failed clinical trials and develops them through clinical trials, potentially earning milestone payments and royalties upon successful development and commercialization. Revenue is generated through drug development outcomes, partnering deals, and eventual product commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify promising molecules from failed clinical trials. The company acquires or licenses these failed drug candidates and uses AI analysis to reposition them for new therapeutic indications, focusing on late-stage programs in life-threatening diseases with urgent unmet medical needs such as sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease.

Product overview

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify and develop promising molecules from failed clinical trials. Rather than starting drug discovery from scratch, the company acquires or licenses failed drugs and uses AI analysis to reposition them for new therapeutic indications. The company maintains multiple late-stage clinical programs across life-threatening diseases including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. Biossil has expanded its portfolio through strategic acquisitions (dismutase mimetics portfolio from Galera including avasopasem and rucosopasem) and licensing agreements (remetinostat from Medivir), with additional programs in hereditary xerocytosis, MPS VI, diabetic cardiomyopathy, and other rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• AI Drug Rescue Platform
• Sickle Cell Disease Program
• Idiopathic Pulmonary Fibrosis Program
• Glioblastoma Program
• Breast Cancer Program
• Alzheimer's Disease Program
• Remetinostat
• Avasopasem
• Rucosopasem
• Rivipansel
• Odiparcil
• Caficistat
• Reltecimod

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Partnerships

Four partnerships are on record, tiered core.

• Medivir ABcoreOEM/ Whitelabel/ Licensing Partner · 23 October 2025Biossil received exclusive global rights from Medivir to develop and commercialize remetinostat, a topical HDAC inhibitor in phase 2 trials. Medivir could receive up to USD 60 million in milestone payments and royalties if the drug is approved.
• Medivir ABcoreOEM/ Whitelabel/ Licensing Partner · 23 October 2025Exclusive licensing agreement for remetinostat development rights, a topical HDAC inhibitor. Biossil assumes global development responsibilities with potential milestone and royalty payments to Medivir.
• Galera TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 22 October 2025Biossil acquired Galera Therapeutics' dismutase mimetics portfolio including avasopasem and rucosopasem for up to $105 million. Biossil assumes development and commercialization obligations including royalties, with the assets in clinical trials for head and neck cancer and pancreatic cancer.
• Galera TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 22 October 2025Asset Purchase Agreement for dismutase mimetics portfolio acquisition including all formulations and indications, with potential total value up to $108.5 million. Biossil assumed ongoing development and commercialization obligations.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Biovie: Clinical-stage company developing repositioned therapeutics including drugs originally developed by larger pharmaceutical companies. Comparable in pursuing late-stage repositioning plays for unmet-need indications.

Direct peers

• Recursion Pharmaceuticals: Clinical-stage AI-native biopharma combining high-throughput biology with machine learning to advance a multi-indication pipeline. Closely comparable to Biossil's AI-platform + late-stage clinical asset model.
• Xaira Therapeutics: AI-native drug discovery startup funded to apply frontier AI models to therapeutics development. Comparable as a recent, well-capitalized AI-biotech entrant pursuing a similar platform-plus-pipeline strategy.
• Schrödinger: Computational drug discovery platform with both internal pipeline and partnered programs. Comparable in using physics- and ML-based methods to accelerate small-molecule drug discovery.
• Generate Biomedicines: AI-first biologics design company using generative models to create novel protein therapeutics. Comparable as a well-funded AI-native biopharma pursuing a platform-plus-pipeline model.
• Exscientia: AI-driven precision medicine company developing small-molecule therapeutics using automated drug design. Comparable as an early AI-drug-discovery company that has progressed multiple candidates into the clinic.
• BenevolentAI: AI drug discovery company applying machine learning to identify new drug targets and reposition existing assets. Comparable in using AI specifically for drug repositioning and indication selection across multiple programs.
• Insitro: AI-driven drug discovery company using machine learning on human data to develop therapeutics across multiple indications. Comparable in being an AI-native platform company translating computational methods into clinical assets.
• Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind. Comparable as a high-profile AI-native biopharma applying foundation models to therapeutic discovery and development.

Others

• Galera Therapeutics: Clinical-stage biotech whose dismutase mimetics portfolio was acquired by Biossil. Highly relevant counterparty: Biossil is essentially continuing Galera's oncology supportive-care pipeline (avasopasem, rucosopasem) in head & neck, pancreatic, and other cancers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biossil